<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827605</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_FLAZ-12</org_study_id>
    <nct_id>NCT01827605</nct_id>
  </id_info>
  <brief_title>A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)</brief_title>
  <official_title>A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, open-label, randomized and controlled study to compare the
      efficacy of a consolidation therapy with RIT versus ASCT in patients with FL in CR or PR
      after second or third line chemotherapy supplemented with rituximab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, open-label, randomized and controlled study to compare the
      efficacy of a consolidation therapy with RIT vs. ASCT in patients with FL in CR or PR after
      second or third line chemotherapy supplemented with rituximab. Patients with FL will be
      eligible for screening at the time of relapsed or refractory disease after two or less
      chemotherapy lines at least one containing rituximab.

      This study will be conducted in six steps as follows. Screening Phase, Enrolment and
      Induction chemotherapy (STEP I) Randomization (STEP II) Stem cell mobilization and collection
      (STEP III) Consolidation (RIT vs ASCT) (STEP IV) Maintenance (STEP V) Follow-up Phase (STEP
      VI)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival from randomization (rPFS)</measure>
    <time_frame>36 months</time_frame>
    <description>PFS will be defined as the time between the date of randomization and the date of disease progression, relapse or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from randomization (rOS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS will be defined as the time between the date of randomization and the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>36 months</time_frame>
    <description>EFS will be measured from the date of randomization to the date of any treatment failure including death, disease progression or relapse, discontinuation of treatment for any reason (toxicity, patient preference, initiation of new treatment without documented progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Free Survival from randomization (TFS)</measure>
    <time_frame>36 months</time_frame>
    <description>TFS will be defined as the time between the date of the end of primary treatment until the institution of the next unplanned chemotherapy in randomized population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival from enrolment (ePFS)</measure>
    <time_frame>42 months</time_frame>
    <description>PFS will be defined as the time between the date of enrolment and the date of disease progression, relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from enrolment (eOS)</measure>
    <time_frame>42 months</time_frame>
    <description>OS will be defined as the time between the date of enrolment and the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>At the end of the consolidation phase (6 months)</time_frame>
    <description>Proportion of CR according to the Cheson 2007 response criteria at the end of consolidation phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>At the end of the consolidation phase (6 months)</time_frame>
    <description>ORR at the end of the consolidation phase is defined as Complete Response (CR) or Partial Response according to the Cheson 2007 response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>42 months</time_frame>
    <description>Incidence of grade 3 or higher Toxicity measured by CTCAE v.4.03 during therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response rate (MR)</measure>
    <time_frame>36 months</time_frame>
    <description>Rate of MR will be defined as the proportion of patients achieving PCR negativity after the consolidation phase and during follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Response rate conversion (cMR)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of conversion will be defined as the proportion of patients with baseline PCR-positivity converting to PCR-negativity during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Relapse Rate (MRR)</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of molecular relapse will be defined as the proportion of patients with PCR-negativity after treatment converting to PCR-positivity during the first two years of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Relapsed Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A RIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B ASCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BEAM conditioning regimen (or in alternative FEAM regimen with fotemustine to replace BCNU) and reinfusion of CD34+ cells of ≥ 2x106/Kg CD34+ day 0 (optimal dose to reinfuse 4x106/Kg CD34+). G-CSF 5 mcg/Kg from day 2 until ANC&gt;1500/mmc. Patients who failed mobilization will directly proceed to rituximab maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ZEVALIN</intervention_name>
    <description>Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).</description>
    <arm_group_label>Arm A RIT</arm_group_label>
    <other_name>RIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEAM</intervention_name>
    <description>BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution
from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr
day 0
UReinfusion of autologous stem cells following this rules:
Patient collecting ≥6x106 CD34+ cells/kg use &gt;4x106 CD34+ cells/kg for ASCT and keep &gt;2x106 CD34+ cells/kg for back up;
Patient collecting 4-6x106 CD34+ cells/kg use &gt;2x106 CD34+ cells/kg for ASCT and keep &gt;2x106 CD34+ cells/kg for back up;
Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.
day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC &gt; 1500/mmc</description>
    <arm_group_label>ARM B ASCT</arm_group_label>
    <other_name>ASCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  Histologically documented diagnosis of grade I-IIIa FL defined according to WHO
             guidelines 2008 (Re-biopsy required)

          -  Availability of BM and PB for Minimal Residual Disease (MRD) analysis (see Appendix I)

          -  Relapsed or refractory disease after ≤ two chemotherapy lines at least one containing
             Rituximab (Rituximab maintenance is UNOTU considered a therapeutic line)

          -  Clinical indication of treatment i.e. Stage II-IV who require therapy according to SIE
             and GELF criteria (see Appendix II)

          -  ECOG performance status 0-2 (unless disease-related) (see Appendix III)

          -  Availability of histological material for centralized revision

          -  Laboratory values:

               -  ANC ≥ 1500/mmc unless due to marrow involvement by lymphoma and/or platelets ≥
                  100000/mmc unless due to marrow involvement by lymphoma

               -  Serum creatinine ≤ 1.5 x ULN, unless it is disease related

               -  Bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN, if patient has Gilbert syndrome)

               -  AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN if not lymphoma related or ≤ 5.0 x ULN in
                  case of lymphoma liver involvement

          -  Adequate cardiac function: LVEF &gt; 50% by echocardiography or MUGA scan

          -  Not pregnant or breast-feeding

          -  Willingness to use effective contraception during the study and 3 months after the end
             of treatment

          -  No other prior malignancies except for adequately treated non-melanoma skin cancer,
             carcinoma in situ of the cervix, or other cancer from which the patient has been
             disease-free for ≥ 5 years (see Exclusion criteria 14)

          -  Signed informed written consent

        Exclusion Criteria:

          -  Grade IIIb FL, transformed FL or histologies different from FL

          -  Previous treatment with &gt; two lines of chemotherapy ± rituximab Maintenance is UNOTU
             considered a therapeutics line)

          -  Previous ASCT or RIT treatment

          -  CNS involvement by lymphoma

          -  HBV positivity with the exception of patients who are seropositive because of
             hepatitis B virus vaccination and patients HbcAb positive and HbsAg negative with
             undetectable serum HBV-DNA. Occult carriers: must receive treatment with Lamivudine
             100 mg for the duration of treatment program and at least 12 months after treatment
             cessation; HBV-DNA levels and HBsAg will be monitored every month

          -  HCV positivity with elevated transaminases or INR or APTT or active virus replication

          -  HIV positivity

          -  Any concurrent medical condition requiring long term use (&gt; one month) of systemic
             corticosteroids

          -  Active bacterial, viral, or fungal infection requiring systemic therapy

          -  Any concurrent medical or psychiatric condition which might impair administration of
             therapy or preclude the ability to give informed consent

          -  Treatment with an experimental agent within 30 days prior to study entry

          -  Myelosuppressive chemo or biological therapy within three weeks before study entry
             (use rituximab course delivered as maintenance is not an exclusion therapy)

          -  Major surgery other than diagnosis within 4 weeks prior to study entry

          -  Previous i.v. or i.m. treatments with murine or animal derived antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO Città della salute e della Scienza di Torino - Ospedale S. Giovanni Battista - TORINO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Ladetto</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO SS. Antonio e Biagio e Cesare Arrigo Alessandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS‐Centro di riferimento oncologico UO di ematologia e Trapianto Cellule Staminali</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi Melacrino Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero &quot;A. Tortora&quot;</name>
      <address>
        <city>Pagani</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emat Univ - Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di ematologia AOU Umberto I Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia con Trapianto Policlinico Universitario Consorziale</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Bolzano Divisione di Ematologia e Centro Trapianti di Midollo Osseo</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero A.Perrino - Divisione di Ematologia</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp. Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCC Onco-Ematologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Garibaldi-Nesima</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Careggi Clinica Ematologica</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A O Papardo</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Policlinico Universitario AOU G. Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Unità di Chamioterapia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena - Università degli studi</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Pascale Oncoematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia ‐ Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera V. Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Ematologia Ospedale di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito Dipartimento di Ematologia</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Ematologia Ospedale Civile di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ausl Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO Santa Maria Nuova IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.S.Andrea Reparto di Ematologia e Immunoematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristà La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Filippo Gherlizoni</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Osp. Cardinale Panico</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia - A.O.U. S. Maria di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed follicular Lymphoma</keyword>
  <keyword>RIT</keyword>
  <keyword>Zevalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

